Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters

作者：Changzheng Wang, Rongrong Deng, Liyao Gou, Zhongxiao Fu, Xiaomei Zhang, Feng Shao, Guanzhen Wang, Weiyang Fu, Jianping Xiao, Xiao Ding, Tao Li, Xiulin Xiao, Chengbin Li · 发表于：Annals of Translational Medicine · 年份：2020 · DOI：10.21037/atm-20-3391 · 被引用次数：228 · 研究领域：Inflammatory Biomarkers in Disease Prognosis、COVID-19 Clinical Research Studies、Digital Imaging for Blood Diseases

BACKGROUND: The third fatal coronavirus is the novel coronavirus (SARS-CoV-2) that causes novel coronavirus pneumonia (COVID-19) which first broke out in December 2019. Patients will develop rapidly if there is no any intervention, so the risk identification of severe patients is critical. The aim of this study was to investigate the characteristics and rules of hematology changes in patients with COVID-19, and to explore the possibility differentiating moderate and severe patients using conventional hematology parameters or combined parameters. METHODS: The clinical data of 45 moderate and severe type patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Jingzhou Central Hospital from January 23 to February 13, 2020 were collected. The epidemiological indexes, clinical symptoms, and laboratory test results of the patients were retrospectively analyzed. Those parameters with significant differences between moderate and severe cases were analyzed, and the combination parameters with the best diagnostic performance were selected using the linear discriminant analysis (LDA) method. RESULTS: Of the 45 patients with the novel 2019 corona virus (COVID-19) (35 moderate and 10 severe cases), 23 were male and 22 were female, with ages ranging from 16 to 62 years. The most common clinical symptoms were fever (89%) and dry cough (60%). As the disease progressed, white blood cell count (WBC), neutrophil count, neutrophil-to-lymphocyte ratio (NLR), plate...